Educational guide for research and informational purposes only. Not medical advice.
CJC-1295 and Ipamorelin are the most widely used GH secretagogue combination in peptide protocols — and for good reason. They work through complementary mechanisms that, when combined, produce GH pulses significantly greater than either compound alone. Understanding why requires a clear picture of how growth hormone is actually regulated.
Growth Hormone Regulation — The Two-Signal System
GH secretion from the anterior pituitary is controlled by two opposing signals:
- GHRH (Growth Hormone-Releasing Hormone) — stimulatory; produced in the hypothalamus; binds GHRH receptors on somatotroph cells to trigger GH synthesis and release
- Somatostatin — inhibitory; also hypothalamic; suppresses GH release, creating the pulsatile pattern of natural GH secretion
- Ghrelin / GHRP (Growth Hormone-Releasing Peptides) — a third input via ghrelin receptors (GHS-R1a) that amplifies GH release and also suppresses somatostatin, creating a complementary stimulatory signal
CJC-1295 activates the first pathway (GHRH receptor). Ipamorelin activates the third (ghrelin receptor). Combining them hits both stimulatory mechanisms simultaneously while somatostatin suppression from the ghrelin receptor pathway further amplifies the effect. The result: GH pulses that are larger and more sustained than either compound achieves alone — without exceeding the physiological range, since the feedback mechanisms remain intact.
CJC-1295 — Modified GHRH Analog
Structure and Pharmacology
CJC-1295 is a synthetic analog of the first 29 amino acids of endogenous GHRH, with several amino acid substitutions that protect the molecule from DPP-IV (dipeptidyl peptidase IV) degradation — the primary enzyme that inactivates native GHRH within minutes of secretion.
Two versions exist with fundamentally different pharmacokinetic profiles:
| Version | Also Known As | Half-Life | GH Pulse Pattern | Best For |
|---|---|---|---|---|
| CJC-1295 without DAC | Mod GRF(1-29) | ~30 minutes | Pulsatile (physiologic) | Stacking with Ipamorelin; pre-sleep pulse |
| CJC-1295 with DAC | CJC-1295 DAC | ~7–8 days | Sustained elevation ("GH bleed") | Once or twice weekly injection convenience |
DAC (Drug Affinity Complex) is a lysine-maleimide linker that allows the peptide to bind covalently to circulating albumin, dramatically extending its half-life. The trade-off: the prolonged half-life produces sustained, continuous GH elevation rather than discrete pulses — which may increase the risk of side effects (water retention, carpal tunnel symptoms, glucose dysregulation) associated with non-physiologic GH patterns.
For most protocols, CJC-1295 without DAC (Mod GRF 1-29) is preferred when combined with Ipamorelin — it produces the pulsatile GH pattern that more closely mimics natural physiology and allows the negative feedback system to function normally between doses.
Mechanism of Action
- Binds GHRH receptor on anterior pituitary somatotrophs
- Activates adenylate cyclase → increases intracellular cAMP → triggers GH synthesis and exocytosis
- Maintains pituitary sensitivity with pulsatile dosing (does not downregulate GHRH receptors when administered intermittently)
- Stimulates somatotroph proliferation with prolonged use — the pituitary gland increases its GH-producing capacity over time
Ipamorelin — The Selective Ghrelin Receptor Agonist
Structure and Key Properties
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the ghrelin receptor (GHS-R1a). It was developed to provide GH secretagogue activity without the cortisol, prolactin, and ACTH elevation seen with earlier GHRPs (GHRP-2, GHRP-6).
This selectivity is the defining characteristic of Ipamorelin: it produces GH release with minimal off-target hormonal effects. GHRP-6, by comparison, strongly increases appetite (through the same ghrelin receptor) and raises cortisol significantly. Ipamorelin's selectivity profile makes it more appropriate for extended use.
Mechanism of Action
- GHS-R1a agonism — activates ghrelin receptors on pituitary somatotrophs, triggering GH release via a calcium-dependent mechanism (IP3 pathway) distinct from the cAMP pathway activated by GHRH
- Somatostatin suppression — ghrelin receptor activation suppresses somatostatin release at the hypothalamic level, reducing inhibitory tone on GH secretion during the pulse window
- Synergy with GHRH pathway — because Ipamorelin and CJC-1295 activate different intracellular signaling cascades (IP3 vs. cAMP), their combination is genuinely synergistic rather than simply additive
- Minimal cortisol effect — unlike GHRP-2, Ipamorelin does not significantly raise cortisol at standard doses; this is important for protocols aimed at body composition, where elevated cortisol undermines the anabolic effects of GH
What GH Does — The Downstream Effects
Both compounds work because of what growth hormone itself does throughout the body:
- Direct lipolysis — GH activates hormone-sensitive lipase in adipose tissue, mobilizing stored triglycerides for oxidation; this effect is most pronounced in visceral fat depots
- IGF-1 stimulation — GH stimulates hepatic IGF-1 production; IGF-1 mediates the anabolic effects of GH on muscle, bone, and connective tissue (protein synthesis, satellite cell activation, collagen production)
- Anti-catabolic effects — GH and IGF-1 reduce muscle protein breakdown; critical during caloric restriction to preserve lean mass
- Metabolic shift — GH shifts fuel utilization toward fat oxidation and away from glucose and amino acid catabolism — the metabolic signature of fat loss with lean mass preservation
- Connective tissue support — IGF-1 drives collagen synthesis in tendons, ligaments, and cartilage; this is the mechanism behind the injury prevention and recovery benefits users commonly report
- Sleep quality — the majority of daily GH secretion occurs during slow-wave sleep; well-functioning GH axis supports deeper, more restorative sleep; conversely, improved sleep quality (from evening injection timing) further amplifies the natural nocturnal GH pulse
Protocol — Timing and Dosing
Standard Combined Protocol
- CJC-1295 without DAC: 100–200mcg per injection
- Ipamorelin: 100–300mcg per injection
- Combined in same syringe (compatible in solution) or sequential injections
- Administration: subcutaneous (abdomen preferred for rapid absorption)
Timing Strategy
The single most important timing factor: inject on an empty stomach or at least 2 hours post-meal. Elevated insulin and blood glucose suppress somatotroph response — the GH pulse from the injection will be significantly blunted if insulin is elevated at time of administration.
- Before sleep (most common): Aligns with the natural nocturnal GH pulse; fasted state (assuming no late eating); maximizes recovery and body composition effects during sleep
- Post-workout: Capitalizes on the exercise-induced GH pulse amplification; fasted or 2hr post-meal; synergizes with training stimulus for lean mass support
- Morning (fasted): Second most common; allows daytime IGF-1 signaling; some users prefer the cognitive and energy effects of morning GH elevation
- Twice daily (advanced): Pre-sleep + morning fasted; maximizes daily GH exposure; more aggressive protocol for body composition goals
Duration and Expectations
- Weeks 1–4: IGF-1 begins to rise; sleep quality improvements frequently reported in weeks 2–3; mild water retention possible (transient)
- Weeks 4–12: Body composition changes become measurable — typically 1–2% reduction in body fat percentage, preservation or modest gain in lean mass
- Weeks 12–24: Compounding effects; connective tissue improvements; continued body composition improvement at consistent dosing
- Minimum effective cycle: 12 weeks; 20–24 week cycles are standard for meaningful body composition outcomes
Stack Integration
The GLP-1 + GH Axis Stack (Most Popular)
- Semaglutide + B12 or Tirzepatide + B12 — GLP-1 therapy creates the caloric deficit
- CJC-1295 / Ipamorelin 10mg/10mg — GH axis support preserves lean mass and accelerates fat mobilization during deficit
The Recovery + Lean Mass Stack
- CJC-1295 / Ipamorelin — GH pulse optimization
- Wolverine (BPC-157 / TB-500) — tissue repair and injury prevention
References
- Ionescu M, Frohman LA. Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797.
- Raun K, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
- Nass R, et al. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults. Ann Intern Med. 2008;149(9):601–611.
- Veldhuis JD, et al. Differential Impact of Age, Sex Steroid Hormones, and Obesity on Basal vs. Pulsatile Growth Hormone Secretion. Am J Physiol. 1995;268(6):E1196–E1204.
- Tannenbaum GS, Bowers CY. Interactions of Growth Hormone Secretagogues and Growth Hormone-Releasing Hormone/Somatostatin. Endocrine. 2001;14(1):21–27.
Educational Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before initiating any peptide protocol.
FitAF Performance — Educational content only.
